BioCryst Reports Second Quarter 2009 Financial Results And Provides Corporate Update
... Phase 2 study of forodesine for the treatment of cutaneous T-cell lymphoma (CTCL). The target enrollment ... nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL). Utilizing crystallography ... that the pivotal trial with forodesine in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint; ...Basic Facts and Statistics About Lupus
... are several forms of lupus, the most common being cutaneous and systemic. cutaneous lupus is limited to the skin and is often ... such as the scalp, face, neck, hands, and arms. cutaneous lupus accounts for approximately 10% of all ....U.S. FDA Approves New THERAKOS(TM) CELLEX(TM) Photopheresis System
... - Integrated System Treats cutaneous T-cell Lymphoma - EXTON, Pa., March 23 ... of the skin manifestations (appearance) of cutaneous T-cell lymphoma (CTCL) that are unresponsive to ... said Larisa J. Geskin, MD, FAAD, Director of cutaneous Oncology and Photopheresis Unit and Dermatology ...Skin Pain, Sensitivity Rises With Migraine
... migraines may also experience a condition called cutaneous allodynia. cutaneous allodynia is skin sensitivity and pain so severe ... jewelry can cause pain. "The phenomenon of cutaneous allodynia seems to be correlated to true ...BioCryst Provides Forodesine HCl Update
... HCl in the treatment of patients with refractory cutaneous T-cell lymphoma (CTCL) at the annual meeting of ... "Response to Oral Forodesine in Refractory cutaneous T-Cell Lymphoma: Interim Results of a Phase ... defined as either complete response or partial cutaneous response that is sustained for at least 28 days. ...Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
... in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). "Based on our experience ... patients with either relapsed or refractory cutaneous T- cell lymphoma will receive PDX as part of a ... at http://www.clinicaltrials.gov . About cutaneous T-cell Lymphoma ...BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
... patients in the pivotal Phase 2 study of forodesine for the treatment of cutaneous T-cell lymphoma. The target enrollment for this study is approximately ... general may not be successful; that the pivotal trial with forodesine in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint; that development and ...SS-A (Ro)Anti-Extractable Nuclear Antigen (ENA) Antibodies Kit
Description:... nuclear antigens (ENA) [RNP, Sm, SS-A (Ro), or SS-B (La)] in human serum. SS-A (Ro) and SS-B (La) antibodies aid in the diagnosis of SLE, subacute cutaneous lupus erythematosus (SCLE) and Sjgrens ....NYU Langone Medical Center awarded NIH grants totaling $1,560,000
... Internal Medicine, chair of the Department of Medicine, and professor of microbiology, will receive support for his study titled "Evaluation of the cutaneous Microbiome in Psoriasis." Psoriasis, affecting more than 7.5 million people in the United States, is a chronic disease involving the immune system ...Blue light destroys antibiotic-resistant staph infection
... colonies. The effectiveness of blue light in vitro suggests that it should also be effective in human cases of MRSA infection, and particularly in cutaneous and subcutaneous infections. "It is inspiring that an inexpensive naturally visible wavelength of light can eradicate two common strains of MRSA. ...Closing the gap: Journal launch brings together wound-healing knowledge
... in skin correlates with myofibroblast induction, and that CTGF-expressing pericytes are significant contributors to myofibroblast activity during cutaneous tissue repair. Commenting on the paper, the Editor in Chief of the new journal, Massimo Pinzani, said, "This is a good example of the type of high ...Researchers find cancer-inhibiting compound under the sea
... 30 labs exist worldwide and research dollars have only become available in the past 15 years. HDACs are already targeted by a drug approved for cutaneous T-cell lymphoma manufactured by the global pharmaceutical company Merck & Co. Inc. However, UF's compound does not inhibit all HDACs equally, meaning ...As rates rise, researchers find better way to identify melanoma
... been rising among older adults. The pilot study investigated samples of 56 biopsied lesions from 48 adults. The lesions fell into the category of cutaneous melanocytic neoplasms, a diverse group that includes benign moles; Spitz nevi, a type of mole seen in younger people that can be easily mistaken for ...Anthrax cellular entry point uncovered
... clever enough to target the Mac-1 receptor, and use this entry point to boost its lethality. Bacillus anthracis infection occurs in three forms: cutaneous (skin), inhalation and through swallowing spores. The skin infection is the most common type and can be treated with antibiotics if diagnosed ....Eric D. Whitman, MD to Present on the Delcath PHP System(TM) at the 7th World Congress on Melanoma
... Percutaneous Isolated Hepatic Perfusion for cutaneous and Uveal Metastatic Melanoma , will discuss his ... to the liver to treat patients with metastatic cutaneous and ocular melanoma who have unresectable tumors ... a Joint Meeting covering the entire spectrum of cutaneous malignancies. Clinicians and researchers will ...AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights
... first oral drug for the treatment of visceral and cutaneous leishmaniasis. Impavido(R) has been proven to be ... by the bite of the phlebotomine sandfly. The cutaneous form of the disease normally produces skin ulcers ... are more than one million new cases per year of cutaneous leishmaniasis and an estimated prevalence of 12 ...Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development
... with chemotherapy; (ii) TG1042, for relapsed cutaneous B-cell Lymphoma, where we expect phase II ... - TG1042 (Ad-IFNγ) for the treatment of relapsed cutaneous B-cell lymphoma (CBCL). A phase II trial was ... of 41 patients suffering from relapsed cutaneous B-cell lymphoma after treatment with ....BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
... -- Forodesine HCl pivotal trial in patients with cutaneous t-cell lymphoma In October, BioCryst began ... oncology drug candidate, forodesine HCl for cutaneous t-cell lymphoma (CTCL). As presented at the ... that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, ...